Estatinas en prevención de enfermedad cardiovascular y cerebrovascular ¿Dónde estamos?

Publicado

2006-04-01

Estatinas en prevención de enfermedad cardiovascular y cerebrovascular ¿Dónde estamos?

Statins and cardiovascular disease where are we going?

Descargas

PDF
HTML

Autores/as

Iván Dario Sierra Ariza MD, PhD. Profesor Titular y Maestro Universitario División de Lípidos y Diabetes Facultad de Medicina Universidad Nacional de Colombia - Bogotá

Resumen (es)

La enfermedad cardiovascular, incluyendo la enfermedad coronaria, es la causa más importante de muerte tanto en hombres como en mujeres en los países desarrollados y también en muchos de los en vías de desarrollo

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Multiple RisK Factor Intervention Trial. Risk Factor Changes and Mortality Results. JAMA,1982;248: 1465-77.

Shepard J, Cobbe SM, Ford L, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia . N Engl J Med 1995;333:1301-7.

Downs JR, Clearfield M, Weis S, et al; for the AFCAPS/TexCAPS Research Group Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels Results of AFCAPS/TexCAPS . JAMA. 1998;279:1615-22. AFCAPS/TexCAPS.

Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96 CARDS.

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9 4S.

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Eng J Med 1998; 339: 1349-57 LIPID.

Sacks FM, Pfeffer MA, Moyé LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol leveles. New Engl J Med 1996;335:1001-09 CARE.

Sever PS, Dahlöf B, Poulter NR et al. for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT- LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58 ASCOT-LLA.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet. 2002; 360: 7-22. HPS.

Shepherd J, Blauw GJ, Murphy MB et al on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet. 2002; 360: 1623-30. PROSPER.

Schwartz GG, Olsson AG, EzekowitzMD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: a randomized controlled Trial. JAMA.2001;285:1711-8 MIRACL.

Cannon CP, Braunwald E, McCabe CH, et al. Comparasion of Intensive and Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 2004;350:1495-504 PROVE-IT.

Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis.JAMA 2004;291:1071-80 REVERSAL.

Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin terapy on regression of coronary atherosclerosis. JAMA 2006; Published online March 13. The ASTEROIDE TRIAL.

Cholesterol Treatment Trialists (CIT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective mata-analysis of data from 90056 participants in 14 randimised trials of statins. Lancet. 2005; 366: 1267-78.

Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA Reductase Inhibitors on Stroke. A Meta-Analysis of Randomized, Controlled Trials. Ann Inter Med 1998; 128: 89-95.

Wagstaff LR, Mitton MW, McLendon Arvik B et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003; 23(7): 871-80.

Wood WG, Koudinov AR, Ohm TG et al. Cholesterol and Alzheimer Disease (Symposium Abstracts). Neurobiol Lipids 2002; 1,4 http://neurobiologyolipids.org/content/1/4.

Jick H, Zornberg GL, Jick SS et al. Statins and the risk of dementia. Lancet 2000; 356: 162731.